Maxillofacial Plastic and Reconstructive Surgery

  • Volume 41
  • /
  • Pages.56.1-56.6
  • /
  • 2019
  • /
  • 2288-8101(pISSN)
  • /
  • 2288-8586(eISSN)
Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지
DOI QR코드

DOI QR Code

PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma

  • Tojyo, Itaru (Department of Oral and Maxillofacial Surgery, Wakayama Medical University) ;
  • Shintani, Yukari (Department of Oral and Maxillofacial Surgery, Wakayama Medical University) ;
  • Nakanishi, Takashi (Department of Oral and Maxillofacial Surgery, Wakayama Medical University) ;
  • Okamoto, Kenjiro (Department of Oral and Maxillofacial Surgery, Wakayama Medical University) ;
  • Hiraishi, Yukihiro (Department of Dentistry and Oral Surgery, Japanese Red Cross Wakayama Medical Center) ;
  • Fujita, Shigeyuki (Department of Oral and Maxillofacial Surgery, Wakayama Medical University) ;
  • Enaka, Mayu (Department of Pathology, Wakayama Medical University) ;
  • Sato, Fuyuki (Department of Pathology, Wakayama Medical University) ;
  • Muragaki, Yasuteru (Department of Pathology, Wakayama Medical University)
  • Received : 2019.09.06
  • Accepted : 2019.11.06
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule that attenuates the immune response. PD-L1 contributes to failed antitumor immunity; thereby, blockade of PD-L1 with monoclonal antibody enhances the immune response. Recently, it was reported that PD-L1 was regulated by protein 53 (p53). Besides, cytokeratin 17 (CK17) is thought to be a diagnostic marker of oral squamous cell carcinoma (OSCC). Our aim was to evaluate the correlation between the immunohistochemical expression of PD-L1, p53 and CK17 with clinicopathological characteristics and disease-specific survival in patients with OSCC. Methods: A total of 48 patients with OSCC were included in this study. Immunohistochemical staining was performed to evaluate the correlation among the expressions of PD-L1, p53 and CK17, and furthermore the correlation among various clinicopathological factors, PD-L1, p53 and CK17. Results: The positive rate of p53, CK17, PD-L1 (tumor cells) and PD-L1 (tumor-infiltrating lymphocytes) was 63.2%, 91.7%, 48.9% and 57.1%. A statistically significant correlation between p53 expression and T stage and TNM stage (p = 0.049, p = 0.03, respectively) was observed. Also, a statistically significant correlation between p53 and PD-L1 (TCs) expression (p = 0.0009) was observed. Five-year disease-specific survival rate was not significantly correlated with gender, TNM stage, p53 expression, PD-L1 expression and CK17 expression. Conclusion: The expression of p53 and PD-L1 shows significantly positive correlation in oral squamous cell carcinoma in tumor cells. Also, a significant correlation between p53 expression and T stage and TNM stage was observed. No other significant correlation between PD-L1 staining or CK17 and clinical or pathologic characteristics was identified.

Keywords

References

  1. Sharmal P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56-61 https://doi.org/10.1126/science.aaa8172
  2. Maruse Y, Kawano S, Jinno T, Matsubara R, Goto Y, Kaneko N et al (2018) Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg 47:836-845 https://doi.org/10.1016/j.ijom.2018.01.004
  3. Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM et al (2015) High PDL1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS ONE 10(11):e0142656. https://doi.org/10.1371/journal.pone.0142656
  4. Pfeifer GP, Holmquist GP (1997) Mutagenesis in the P53 gene. Biochim Biophys Acta 1333(1):M1-M8
  5. Elias J, Dimitrio L, Clairambault J, Natalini R (2014) The p53 protein and its molecular network: modelling a missing link between DNA damage and cell fate. Biochim Biophys Acta 1844(1 Pt B):232-247 https://doi.org/10.1016/j.bbapap.2013.09.019
  6. Li Y, Zhang J (2015) Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy. Oncol Lett 10:2883-2887 https://doi.org/10.3892/ol.2015.3651
  7. Yu X, Zhang X, Wang F, Lin Y, Wang W, Chen Y et al (2018) Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma. J Thorac Dis 10(3):1891-1902 https://doi.org/10.21037/jtd.2018.03.14
  8. Kitamura R, Toyoshima T, Tanaka H, Kawano S, Kiyosue T, Matsubara R et al (2012) Association of cytokeratin 17 expression with differentiation in oral squamous cell carcinoma. J Cancer Res Clin Oncol 138:1299-1310 https://doi.org/10.1007/s00432-012-1202-6
  9. Xu XC, Lee JS, Lippman SM, Ro JY, Hong WK, Lotan R (1995) Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis. Cancer Epidemiol Biomarkers Prev 4(8):871-876
  10. Toyoshima T, Vairaktaris E, Nkenke E, Schlegel KA, Neukam FW, Ries J (2008) Cytokeratin 17 mRNA expression has potential for diagnostic marker of oral squamous cell carcinoma. J Cancer Res Clin Oncol 134(4):515-521 https://doi.org/10.1007/s00432-007-0308-8
  11. Yamamoto E, Kohama G, Iwai M, Hiratsuka H (1983) Mode of invasion, Bleomycin sensitivity and clinical course in squamous cell carcinoma of the oral cavity. Cancer 51:2175-2180 https://doi.org/10.1002/1097-0142(19830615)51:12<2175::AID-CNCR2820511205>3.0.CO;2-M
  12. Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S (2006) Immunohistochemical Expression of EGFR and p-EGFR in Oral Squamous Cell Carcinomas. Pathol Oncol Res 12(2):87-91 https://doi.org/10.1007/BF02893450
  13. Sato F, Bhawal U, Tojyo I, Fujita S, Murata S, Muragaki Y (2019) Differential expression of claudin-4, occluding, SOX2 and proliferating cell nuclear antigen between basaloid squamous cell carcinoma and squamous cell carcinoma. Mol Med Rep 20:1977-1985
  14. Sato F, Kohsaka A, Takahashi K, Otao S, Kitada Y, Iwasaki Y et al (2017) Smad3 and Bmal1 regulate p21 and S100A4 expression in myocardial stromal fibroblasts via TNF-${\alpha}$. Histochem Cell Biol 148:617-624 https://doi.org/10.1007/s00418-017-1597-x
  15. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y et al (2015) PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 108(1): djv303
  16. Gronostajski RM, Goldberg AL, Pardee AB (1984) Energy requirement for degradation of tumor-associated protein p53. Mol Cell Biol 4:442-448 https://doi.org/10.1128/MCB.4.3.442
  17. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539 https://doi.org/10.1128/MCB.8.2.531
  18. Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Ho QH et al (2015) Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol 10:1156-1162 https://doi.org/10.1097/JTO.0000000000000579
  19. Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS (2016) Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer 97:73-80 https://doi.org/10.1016/j.lungcan.2016.05.001

Cited by

  1. Mutant p53 as an Antigen in Cancer Immunotherapy vol.21, pp.11, 2019, https://doi.org/10.3390/ijms21114087
  2. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas vol.477, pp.6, 2019, https://doi.org/10.1007/s00428-020-02867-9
  3. Clinicopathological and prognostic significance of PD‐L1 in oral cancer: A preliminary retrospective immunohistochemistry study vol.27, pp.2, 2021, https://doi.org/10.1111/odi.13509
  4. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer vol.27, 2019, https://doi.org/10.3389/pore.2021.1609826
  5. PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer vol.10, pp.14, 2021, https://doi.org/10.1002/cam4.4034
  6. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells vol.13, pp.7, 2019, https://doi.org/10.4252/wjsc.v13.i7.795
  7. High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments vol.9, pp.9, 2021, https://doi.org/10.3390/biomedicines9091132
  8. Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses vol.6, pp.1, 2021, https://doi.org/10.1038/s41392-020-00382-6